The FDA is Broken. Its Controversial Approval of an Ineffective New Alzheimer’s Drug Proves the Agency Puts Profit Over Public Health & ‘Project Onyx’

July 1, 2021

https://www.yahoo.com/news/fda-broken-controversial-approval-ineffective

The FDA is broken. It’s controversial approval of an ineffective new Alzheimer’s drug proves the agency puts profit over public health.

P.E. Moskowitz
alzheimers research 4x3
The way medicinal science is funded and rubber-stamped in this country has less to do with public health than it does with profit. Skye Gould/Insider
  • The agency’s approval of a new Alzheimer’s drug rightly caused an uproar.
  • But the problems extend far beyond the drug, and far beyond the FDA: Drug science has been corrupted by the pharmaceutical industry.
  • We must get money out of science to have safe and effective drugs.
  • P.E. Moskowitz is an author and runs Mental Hellth, a newsletter about capitalism and psychology.
  • This is an opinion article. The thoughts expressed are those of the author.

Earlier this month, three scientists on an independent panel at the Food and Drug Administration (FDA) resigned after the agency green-lit a drug that the scientists had recommended against approving. The drug, aducanumab, brand name Aduhelm, is designed to help Alzheimer’s patients, but there’s little evidence that it actually works, and monthly infusions of it cost $56,000 a year.  (See link for article)

_________________

https://www.statnews.com/2021/06/29/biogen-fda-alzheimers-drug-approval-aduhelm-project-onyx/

Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug

By Adam Feuerstein , Matthew Herper , and Damian Garde

June 29, 2021

It was perhaps the most contentious drug approval in decades, shocking drug company executives, insurance companies, and politicians alike: The Food and Drug Administration, over the objections of its scientific advisers, backed the first new Alzheimer’s medication since 2003, one that could finally give millions of dementia patients a reason for optimism — and reap billions of dollars for its manufacturer, Biogen. (See link for article)

___________________

**Comment**

According to this, Biogen had discussed the possibility of accelerated approval of aducanumab (Aduhelm) with the FDA long before internal agency documents suggest, an investigation by STAT News found, as well as the fact the company made a powerful alliance with a top FDA official that likely contributed to its success.

Alzheimer’s, similarly to Lyme/MSIDS has been trapped in dogma led by a Cabal.

Yet numerous researchers have doggedly fought against the myopic focus and have found spirochetes in the brains of Alzheimer’s patients:   https://madisonarealymesupportgroup.com/2016/06/09/alzheimers-byproduct-of-infection/, and actor/musician Kris Kristofferson was diagnosed with Alzheimer’s but actually had Lyme disease:  https://madisonarealymesupportgroup.com/2017/01/04/aluminum-alzheimers-ld/  A white paper was written in 2018 with the clarion call to “Find the Alzheimer’s Germ.”

Just another example in a mounting list of under the table shenanigans and severe conflicts of interest by the FDA.  For more:

Category:

Alzheimer's, Treatment

Comments Off on The FDA is Broken. Its Controversial Approval of an Ineffective New Alzheimer’s Drug Proves the Agency Puts Profit Over Public Health & ‘Project Onyx’

%d bloggers like this: